利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.017 秒)

    MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT
    1.
    发明申请
    MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT 有权
    喹诺酮衍生物作为抗生素代谢物的有效盐

    公开(公告)号：US20100298357A1

    公开(公告)日：2010-11-25

    申请号：US12646153

    申请日：2009-12-23

    申请人： James MCCABE

    发明人： James MCCABE

    IPC分类号： A61K31/517 ,  C07D403/12 ,  A61P35/00

    CPC分类号： C07D403/12 ,  A61K31/517 ,  A61K45/06 ,  C07C57/145

    摘要： The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.

    摘要翻译： 本发明涉及AZD2171马来酸盐，AZD2171马来酸盐的特定结晶形式，其制备方法，含有它们作为活性成分的药物组合物，用于制备用于生产抗血管生成和/ 或血管通透性降低效果，以及它们在治疗与血管生成相关的疾病状态和/或增加血管通透性的方法中的用途。

    Quinazoline derivatives
    2.
    发明申请
    Quinazoline derivatives 失效
    喹唑啉衍生物

    公开(公告)号：US20050165035A1

    公开(公告)日：2005-07-28

    申请号：US10857342

    申请日：2004-06-01

    申请人： Robert Bradbury ,  Jason Kettle ,  James McCabe ,  Andrew Turner ,  Laurent Hennequin

    发明人： Robert Bradbury ,  Jason Kettle ,  James McCabe ,  Andrew Turner ,  Laurent Hennequin

    IPC分类号： C07D401/12 ,  A61K31/517 ,  C07D43/02

    CPC分类号： C07D401/12

    摘要： The invention concerns quinazoline derivatives of Formula I wherein R1 and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.

    摘要翻译： 本发明涉及式I的喹唑啉衍生物，其中R 1和R 2具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对erbB特别是EGF受体酪氨酸激酶的抑制敏感的肿瘤中的抗增殖剂的药物中的用途。

    NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR
    4.
    发明申请
    NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR 审中-公开
    新型晶体化合物作为GLK激活剂有用

    公开(公告)号：US20100094009A1

    公开(公告)日：2010-04-15

    申请号：US12520223

    申请日：2007-12-20

    申请人： James McCabe ,  Gary Peter Tomkinson

    发明人： James McCabe ,  Gary Peter Tomkinson

    IPC分类号： C07D401/14

    CPC分类号： C07D403/14

    摘要： A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.

    摘要翻译： 3 - {[5-（氮杂环丁烷-1-基羰基）吡嗪-2-基]氧基} -5 - [（1-甲基乙基）氧基] -N-1H-吡唑-3-基苯甲酰胺的新型结晶形式描述于 规格。 该化合物是葡萄糖激酶（GLK或GK）激活剂，可用作治疗或预防通过GLK介导的疾病或医学病症的药物，导致胰岛素分泌的葡萄糖阈值降低。 还描述了用于制造结晶形式的方法，包含结晶形式的药物组合物和在治疗中使用结晶形式的方法。

    Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
    7.
    发明授权
    Maleate salts of a quinazoline derivative useful as an antiangiogenic agent 有权
    用作抗血管生成剂的喹唑啉衍生物的马来酸盐

    公开(公告)号：US08859570B2

    公开(公告)日：2014-10-14

    申请号：US12646153

    申请日：2009-12-23

    申请人： James McCabe

    发明人： James McCabe

    IPC分类号： A01N43/54 ,  A61K31/517 ,  C07D239/72 ,  C07D401/00

    CPC分类号： C07D403/12 ,  A61K31/517 ,  A61K45/06 ,  C07C57/145

    摘要： The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.

    摘要翻译： 本发明涉及AZD2171马来酸盐，AZD2171马来酸盐的特定结晶形式，其制备方法，含有它们作为活性成分的药物组合物，用于制备用于生产抗血管生成和/ 或血管通透性降低效果，以及它们在治疗与血管生成相关的疾病状态和/或增加血管通透性的方法中的用途。

    Quinazoline derivatives
    8.
    发明申请
    Quinazoline derivatives 审中-公开
    喹唑啉衍生物

    公开(公告)号：US20070099943A1

    公开(公告)日：2007-05-03

    申请号：US11636549

    申请日：2006-12-11

    申请人： Robert Bradbury ,  Jason Kettle ,  James McCabe ,  Andrew Turner ,  Laurent Hennequin

    发明人： Robert Bradbury ,  Jason Kettle ,  James McCabe ,  Andrew Turner ,  Laurent Hennequin

    IPC分类号： A61K31/517 ,  C07D403/02

    CPC分类号： C04B35/632 ,  C07D401/12

    摘要： The invention concerns quinazoline derivatives of Formula I wherein R1 and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.

    摘要翻译： 本发明涉及式I的喹唑啉衍生物，其中R 1和R 2具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对erbB特别是EGF受体酪氨酸激酶的抑制敏感的肿瘤中的抗增殖剂的药物中的用途。

    Crystalline compound
    10.
    发明授权
    Crystalline compound 失效
    结晶化合物

    公开(公告)号：US07696191B2

    公开(公告)日：2010-04-13

    申请号：US11962838

    申请日：2007-12-21

    申请人： James McCabe ,  Gary Peter Tomkinson

    发明人： James McCabe ,  Gary Peter Tomkinson

    IPC分类号： A01N43/00 ,  A61K31/397 ,  A61K31/00 ,  A01N43/58 ,  A61K31/50 ,  A01N43/60 ,  A61K31/495 ,  A61K31/497 ,  A01N43/56

    CPC分类号： C07D403/14

    摘要： A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.

    摘要翻译： 3 - {[5-（氮杂环丁烷-1-基羰基）吡嗪-2-基]氧基} -5 - [（1-甲基乙基）氧基] -N-1H-吡唑-3-基苯甲酰胺的新型结晶形式描述于 规格。 该化合物是葡萄糖激酶（GLK或GK）激活剂，可用作治疗或预防通过GLK介导的疾病或医学病症的药物，导致胰岛素分泌的葡萄糖阈值降低。 还描述了用于制造结晶形式的方法，包含结晶形式的药物组合物和在治疗中使用结晶形式的方法。